期刊文献+

Cyclophosphamide-associated enteritis: A rare association with severe enteritis

Cyclophosphamide-associated enteritis: A rare association with severe enteritis
下载PDF
导出
摘要 Cyclophosphamide is a potent cytotoxic agent used in many clinical settings. The main risks of cyclophosphamide therapy include hematological disorders, infertility, hemorrhagic cystitis and malignancies. Gastrointestinal side effects reported to date are often non-specific and not severe. We present the first case of a fatal small bowel enteritis and pan-colitis which appears to be associated with cyclophosphamide. We aim to raise the readers' awareness of this significant adverse event to facilitate clinical suspicion and early recognition in potential future cases. Cyclophosphamide is a potent cytotoxic agent used in many clinical settings. The main risks of cyclophosphamide therapy include hematological disorders, infertility, hemorrhagic cystitis and malignancies. Gastrointestinal side effects reported to date are often non-specific and not severe. We present the first case of a fatal small bowel enteritis and pan-colitis which appears to be associated with cyclophosphamide. We aim to raise the readers’ awareness of this significant adverse event to facilitate clinical suspicion and early recognition in potential future cases.
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第39期8844-8848,共5页 世界胃肠病学杂志(英文版)
关键词 肠炎 大肠炎 CYCLOPHOSPHAMIDE 小肠 平底锅大肠炎 Enteritis Colitis Cyclophosphamide Small bowel Pan-colitis
  • 相关文献

参考文献1

二级参考文献11

  • 1Takenobu Shimada M.D.,Dr. Nobuo Hiwatashi M.D.,Hideo Yamazaki M.D.,Yoshitaka Kinouchi M.D.,Takayoshi Toyota M.D.Relationship between glucocorticoid receptor and response to glucocorticoid therapy in ulcerative colitis[J].Diseases of the Colon & Rectum.1997(10)
  • 2Arnott ID,McDonald D,Williams A,Ghosh S.Clinical use of Infliximab in Crohn‘s disease:the Edinburgh experience[].Alimentary Pharmacology and Therapeutics.2001
  • 3Riley P,Maillard SM,Wedderburn LR,Woo P,Murray KJ,Pilkington CA.Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis.A review of efficacy and safety[].Rheumatology.2004
  • 4Watts RA,Scott DG,Pusey CD,Lockwood CM.Vasculitis-aims of therapy.An overview[].Rheumatology.2000
  • 5Sands BE,Tremaine WJ,Sandborn WJ,Rutgeerts PJ,Hanauer SB,Mayer L,Targan SR,Podolsky DK.lnfliximab in the treatment of severe,steroid-refractory ulcerative colitis:a pilot study[].Inflammatory Bowel Diseases.2001
  • 6Daperno M,Sostegni R,Scaglione N,Ercole E,Rigazio C,Rocca R,Pera A.Outcome of a conservative approach in severe ulcerative colitis[].Digestive and Liver Disease.2004
  • 7McCune WJ,Golbus J,Zeldes W,et al.Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus[].New England Journal of Medicine The.1988
  • 8Stallmach A,Wittig BM,Moser C,Fischinger J,Duchmann R,Zeitz M.Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease[].Gut.2003
  • 9Drossman DA,Zhiming L,Leserman J, et al.Ulcerative colitis, and Crohn‘s disease health status scales for research, and clinical practice[].Journal of Clinical Gastroenterology.1992
  • 10Kane S V,Schoenfeld P,Sandborn W J,et al.The effectiveness of budesonide therapy for Crohn’ s disease[].Alimentary Pharmacology and Therapeutics.2002

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部